Study Details
A study to assess the efficacy and safety of ASP1941 in Asian subjects with type 2 diabetes mellitus
Terminated/Withdrawn
The study has stopped early and will not start again. Participants were not enrolled (for withdrawn studies), however if participants were enrolled, they are no longer being examined or treated.
Clinicaltrials.gov ID
The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
Astellas Study ID
The unique identification code given by the study sponsor.
1941-CL-2003
EudraCT ID
The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).
N/A
Condition
Diabetes
Phase
These clinical trials are done to confirm that an experimental treatment helps participants who have a specific condition. These clinical trials often compare the experimental treatment to another treatment or, if appropriate, a placebo.
Phase 3
Age
20 years - N/A
Sex
Female & Male
Product
N/A
Type
A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.
Interventional
Trial Dates
Apr 2012 - Oct 2012
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Enrollment number
46
A Phase III, Double-Blind, Randomized, Active Controlled, Monotherapy Study to Assess the Efficacy and Safety of ASP1941 in Asian Subjects with Type 2 Diabetes Mellitus
Study summary
Study documents
Study Documents, including study results, are available after a study is completed or terminated, according to Astellas Transparency policy.
Get More Information
Would you like more information about clinical trial sites that are recruiting participants for A study to assess the efficacy and safety of ASP1941 in Asian subjects with type 2 diabetes mellitus? Contact us by filling our your information to the right and we’ll respond to you.